Medigene AG: Medigene AG announces subscription price for new shares from current capital increase

Not for distribution, publication or forwarding in or into the  United States, Canada, Japan OR Australia

Press release


Medigene AG announces subscription price for new shares from current capital increase

  • Subscription price set at EUR 8.30 per new share
  • Subscription period scheduled to end at 12 noon (CEST) on 30 June 2015

Martinsried/Munich, 26 June 2015. The Executive Management Board of Medigene AG (MDG1, Frankfurt, Prime Standard) today set, with the approval of the company's Supervisory Board, the subscription price for the ongoing capital measure at EUR 8.30 per new share. As announced concurrently with the publication of the cash capital increase on 12 June 2015 this represents the volume weighted average price (VWAP) of Medigene shares (XETRA electronic trading system of Frankfurt Stock Exchange) from the beginning of the subscription period on 16 June 2015 until close of trading on 25 June 2015 of EUR 8.80 less a discount of 5.7%. The ongoing subscription period for the new shares is scheduled to end at 12 noon CEST on 30 June 2015. Any new shares not subscribed for will be offered at the same price to select institutional investors as private placements.

Medigene plans to issue up to approximately 5.6 million new shares by cash contributions for the further development of its clinical and preclinical development of its immunotherapy platforms. For further details on the capital increase, please see the Medigene press release dated 12 June 2015 and on the company's website at

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit

Note: These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction.  The shares (the "Shares") of Medigene AG (the "Company") may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the Company in the United States.

This publication constitutes neither an offer to sell nor a solicitation to buy securities. The offer will be made solely by means of, and on the basis of, a securities prospectus which has been published. The securities prospectus is available free of charge from Medigene AG, Lochhamer Strasse 11, 82152 Planegg/Martinsried, Germany, as well as on the Medigene AG website under

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. Medigene ImmunotherapiesTM and Trianta ImmunotherapiesTM are registered trademarks of Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in select locations only.


Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

To unsubscribe from the press release distribution list, please go to: